Scientific Reports (Oct 2024)
MHC class I polypeptide-related sequence B shedding modulates pancreatic tumor immunity via the activation of NKG2DLow T cells
- Hitoshi Toyoda,
- Atsuo Kuramasu,
- Masahiro Hosonuma,
- Masakazu Murayama,
- Yoichiro Narikawa,
- Junya Isobe,
- Yuta Baba,
- Kohei Tajima,
- Eiji Funayama,
- Midori Shida,
- Yuki Maruyama,
- Aya Sasaki,
- Yuya Hirasawa,
- Toshiaki Tsurui,
- Hirotsugu Ariizumi,
- Tomoyuki Ishiguro,
- Risako Suzuki,
- Sei Kobayashi,
- Atsushi Horiike,
- Noriko Hida,
- Takehiko Sambe,
- Koji Nobe,
- Satoshi Wada,
- Hitome Kobayashi,
- Mayumi Tsuji,
- Shinichi Kobayashi,
- Takuya Tsunoda,
- Yoshifumi Kudo,
- Yuji Kiuchi,
- Kiyoshi Yoshimura
Affiliations
- Hitoshi Toyoda
- Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University
- Atsuo Kuramasu
- Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University
- Masahiro Hosonuma
- Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University
- Masakazu Murayama
- Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University
- Yoichiro Narikawa
- Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University
- Junya Isobe
- Department of Hospital Pharmaceutics, Showa University School of Pharmacy
- Yuta Baba
- Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University
- Kohei Tajima
- Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University
- Eiji Funayama
- Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University
- Midori Shida
- Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University
- Yuki Maruyama
- Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University
- Aya Sasaki
- Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University
- Yuya Hirasawa
- Division of Medical Oncology, Department of Medicine, Showa University School of Medicine
- Toshiaki Tsurui
- Division of Medical Oncology, Department of Medicine, Showa University School of Medicine
- Hirotsugu Ariizumi
- Division of Medical Oncology, Department of Medicine, Showa University School of Medicine
- Tomoyuki Ishiguro
- Division of Medical Oncology, Department of Medicine, Showa University School of Medicine
- Risako Suzuki
- Division of Medical Oncology, Department of Medicine, Showa University School of Medicine
- Sei Kobayashi
- Department of Otorhinolaryngology, Showa University School of Medicine
- Atsushi Horiike
- Division of Medical Oncology, Department of Medicine, Showa University School of Medicine
- Noriko Hida
- Division of Clinical Pharmacology, Department of Pharmacology, Showa University School of Medicine
- Takehiko Sambe
- Division of Clinical Research and Development, Department of Clinical Pharmacy, School of Pharmacy, Showa University
- Koji Nobe
- Pharmacological Research Center, Showa University
- Satoshi Wada
- Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University
- Hitome Kobayashi
- Department of Otorhinolaryngology, Showa University School of Medicine
- Mayumi Tsuji
- Pharmacological Research Center, Showa University
- Shinichi Kobayashi
- Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University
- Takuya Tsunoda
- Division of Medical Oncology, Department of Medicine, Showa University School of Medicine
- Yoshifumi Kudo
- Department of Orthopedic Surgery, Showa University School of Medicine
- Yuji Kiuchi
- Department of Pharmacology, Showa University School of Medicine
- Kiyoshi Yoshimura
- Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University
- DOI
- https://doi.org/10.1038/s41598-024-73712-1
- Journal volume & issue
-
Vol. 14,
no. 1
pp. 1 – 12
Abstract
Abstract Natural killer group 2 member D ligands (NKG2DLs) are expressed as stress response proteins in cancer cells. NKG2DLs induce immune cell activation or tumor escape responses, depending on their expression. Human pancreatic cancer cells, PANC-1, express membrane MHC class I polypeptide-related sequence A/B (mMICA/B), whereas soluble MICB (sMICB) is detected in the culture supernatant. We hypothesized that sMICB saturates NKG2D in NKG2DLow T cells and inhibits the activation signal from mMICB to NKG2D. Knockdown of MICB by siRNA reduced sMICB level, downregulated mMICB expression, maintained NKG2DLow T cell activation, and inhibited NKG2DHigh T cell activation. To maintain mMICB expression and downregulate sMICB expression, we inhibited a disintegrin and metalloproteinase (ADAM), a metalloproteinase that sheds MICB. Subsequently, the shedding of MICB was prevented using ADAM17 inhibitors, and the activation of NKG2DLow T cells was maintained. In vivo xenograft model revealed that NKG2DHigh T cells have superior anti-tumor activity. These results elucidate the mechanism of immune escape via sMICB and show potential for the activation of NKG2DLow T cells within the tumor microenvironment.
Keywords